Accure Therapeutics

Accure Therapeutics awarded total of $1.6M in grants from The Michael J. Fox Foundation and Fonds National de Recherche de Luxembourg to bring first-in-class drug for Parkinson’s disease to clinical trials

Accure to complete required preclinical studies to file IND application for ACT-02 program in 2026 Fonds National de Recherche (FNR) grant will fund Transcend-PD project, designed to evaluate efficacy of ACT-02 in translational iPSC models, to support patient selection and stratification Funding marks significant support for Accure’s asset, which should enter clinical development in 2026....
Torres R+D+I, Baldiri Reixac 4-8, 08028 Barcelona

+34 93 125 86 07